Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 3
1958 1
1959 3
1960 3
1961 5
1962 3
1963 4
1964 4
1965 1
1966 6
1967 1
1968 1
1969 1
1970 1
1973 2
1974 1
1975 1
1976 3
1977 3
1979 2
1984 1
1986 1
1987 1
1988 1
1989 1
1992 2
1997 2
2007 1
2008 1
2010 1
2011 1
2012 1
2014 1
2018 1
2019 1
2021 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Results by year

Filters applied: . Clear all
Page 1
[POLYCYTHEMIA].
REICHARD H. REICHARD H. Sven Lakartidn. 1964 Feb 26;61:629-39. Sven Lakartidn. 1964. PMID: 14140382 Swedish. No abstract available.
Discovery of TAK-041: a Potent and Selective GPR139 Agonist Explored for the Treatment of Negative Symptoms Associated with Schizophrenia.
Reichard HA, Schiffer HH, Monenschein H, Atienza JM, Corbett G, Skaggs AW, Collia DR, Ray WJ, Serrats J, Bliesath J, Kaushal N, Lam BP, Amador-Arjona A, Rahbaek L, McConn DJ, Mulligan VJ, Brice N, Gaskin PLR, Cilia J, Hitchcock S. Reichard HA, et al. J Med Chem. 2021 Aug 12;64(15):11527-11542. doi: 10.1021/acs.jmedchem.1c00820. Epub 2021 Jul 14. J Med Chem. 2021. PMID: 34260228
First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson's Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate.
Sun H, Monenschein H, Schiffer HH, Reichard HA, Kikuchi S, Hopkins M, Macklin TK, Hitchcock S, Adams M, Green J, Brown J, Murphy ST, Kaushal N, Collia DR, Moore S, Ray WJ, English NM, Carlton MBL, Brice NL. Sun H, et al. Among authors: reichard ha. J Med Chem. 2021 Jul 22;64(14):9875-9890. doi: 10.1021/acs.jmedchem.0c02081. Epub 2021 Apr 16. J Med Chem. 2021. PMID: 33861086
[Sclerosing cholangitis].
Reichard H. Reichard H. Nord Med. 1966 Mar 17;75(11):309. Nord Med. 1966. PMID: 5909351 Danish. No abstract available.
[Sclerosing cholangitis].
Perman ES, Reichard H, Wetterfors J. Perman ES, et al. Among authors: reichard h. Lakartidningen. 1966 Mar 30;63(13):1218-20. Lakartidningen. 1966. PMID: 4380674 Swedish. No abstract available.
In Vitro Biotransformation of the Nrf2 Activator Bardoxolone: Formation of an Epoxide Metabolite That Undergoes Two Novel Glutathione-Mediated Metabolic Pathways: Epoxide Reduction and Oxidative Elimination of Nitrile Moiety.
Kamel AM, Bowlin S, Anwar B, Reichard H, Argus J, Blair IA. Kamel AM, et al. Among authors: reichard h. Chem Res Toxicol. 2019 Nov 18;32(11):2268-2280. doi: 10.1021/acs.chemrestox.9b00289. Epub 2019 Oct 25. Chem Res Toxicol. 2019. PMID: 31613099 Free PMC article.
68 results